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Pathophysiology and Clinical RelevanceThe recent review by Corban et al. (1) highlights the
limitations of the literature on myocardial bridges
(MBs) and suggests the need for clearly deﬁned terms
and protocols. For example, to clearly establish the
prevalence of MB, clinical identiﬁcation should
require 2 angiographic views obtained after nitro-
glycerin administration, rather than computed
tomography (whose use should probably be limited to
measuring length and depth). Chest pain, myocardial
infarction, and sudden death are not systematically
associated with MB of any anatomic severity; most
MBs are benign. As Corban et al. (1) note, MBs actually
prevent coronary artery disease (CAD) inside affected
segments. Statements regarding pathophysiology,
clinical indications, and adverse effects in MB require
clearly deﬁned inclusion and exclusion criteria
(symptomatic or asymptomatic MB vs. MB with
associated comorbidities that may inﬂuence clinical
presentation, e.g., hypertrophic cardiomyopathy).
To determine the cause of sporadic ischemic symp-
toms, workup must ﬁrst rule out signiﬁcant CAD;
worsening of systolic, phasic arterial narrowing at
MB sites (by dobutamine testing and angiography);
and, especially, spasticity or endothelial dysfunction
(by acetylcholine testing) (2–4).Subselective intraluminal devices (e.g., pressure or
Doppler wires, intravascular ultrasound catheters)
should be generally avoided outside of experimental
protocols because they can alter MB by inducing
spasm and deforming the affected coronary segment
(2,3). Incidentally, the “half-moon” sign associated
with MB probably results from the ﬁberoptic probe
bending at the MB site; it is not a true marker of MB
severity (only of its presence).
Although fractional ﬂow reserve has been advo-
cated (1,2) as a measure of MB clinical severity and the
prognosis of associated CAD, this measurement does
not reveal the hemodynamic severity of MB, nor does
it reﬂect prognosis, as it can in moderate atheroscle-
rotic lesions. Deﬁnitive study of MB will require large,
controlled, prospective, multicenter investigations
with long-term, objective clinical follow-up. Anything
less will only perpetuate the current state of confusion
and uncertainty about this entity.*Paolo Angelini, MD
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review of the literature. Intern Med 2011;50:2601–6.Myocardial BridgingWe were pleased to see a state-of-the-art review on
myocardial bridging (1), but were surprised by the
authors’ failure to highlight several contemporary
advances in the ﬁeld.
First, it has become clear that traditional adeno-
sine fractional ﬂow reserve (FFR) is inadequate in
testing the hemodynamic signiﬁcance of a myocar-
dial bridge (2). Because myocardial bridging creates
a dynamic stenosis brought on by chronotropic
and inotropic stimulation, simply dilating the artery
